Inferra AI / Company / PFE / Slides
Pfizer — Recasted 2025 and 2024 Product Revenue Tables Presentation deck (company IR deck)
Pfizer (PFE) · 9 slides · Filed Oct 21, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All PFE deck slides
Slide 1 — PFIZER INC. AND SUBSIDIARY COMPANIES
PFIZER INC. AND SUBSIDIARY COMPANIES RECASTED PRODUCT REVENUES TABLES SUPPLEMENTAL INFORMATION Pfizer is providing the attached recasted unaudited historical product revenues tables for each of the quarters and full year 2025 to conform to Pfizer’s new commercial operating structure, as of January 1, 2026, which reflects the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within the Global Biopharmaceuticals Business (Biopharma) reportable segment. Effective January 1, 2026, the commercial structure within the Biopharma reportable segment is as follows: • Pfizer U.S. Commercial Division, which includes the U.S. commercial organization covering Pfizer’s entire product portfolio except for the Global Hospital and Biosimilars organization. • Pfizer International Commercial Division, which includes the ex-U.S. commercial organizations covering Pfizer’s entire product portfolio in all international markets except for the Global Hospital and Biosimilars organization in certain international markets. • Global Hospital and Biosimilars Division, which includes the commercial organization covering Pfizer’s Hospital and Biosimilars product portfolio of off-patent branded and generic sterile injectables and biosimilars except in China, Hong Kong, and certain other international markets. The new commercial structure within Biopharma is designed to better support and optimize performance across the product portfolios: Primary Care, Specialty Care, Oncology, and beginning in 2026 the Hospital and Biosimilars product portfolio. Prior-period amounts reflected in the 2025 Product Revenues Tables have been recasted to conform to the current presentation. These changes have no impact on our previously reported consolidated revenues or net income. For additional information regarding the changes in Pfizer’s commercial operating structure, see the Item 1. Business––Commercial Operations section of Pfizer's 2025 Annual Report on Form 10-K (available at www.pfizer.com and www.sec.gov), Pfizer’s first quarter 2026 earnings release once it is furnished on Form 8-K with the U.S. Securities and Exchange Commission (SEC), which is expected to be on or about May 5, 2026, and Pfizer’s Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2026 once it is filed with the SEC, which is expected to be on or about May 5, 2026.
Slide 2 — PFIZER INC. REVENUES
PFIZER INC. REVENUES FIRST QUARTER 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 13,715 $ 14,879 (8%) (6%) $ 8,374 $ 9,514 (12%) $ 5,341 $ 5,365 ― 4% GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 13,441 $ 14,604 (8%) (6%) $ 8,285 $ 9,426 (12%) $ 5,156 $ 5,178 ― 4% Primary Care $ 5,692 $ 7,206 (21%) (20%) $ 3,577 $ 5,094 (30%) $ 2,115 $ 2,112 ― 5% Eliquis(b) 1,923 2,040 (6%) (4%) 1,299 1,413 (8%) 624 626 ― 5% Prevnar family(c) 1,660 1,691 (2%) (1%) 1,170 1,149 2% 491 542 (9%) (6%) Comirnaty 565 354 60% 62% 229 118 94% 335 236 42% 45% Paxlovid(d) 491 2,035 (76%) (75%) 347 1,800 (81%) 145 234 (38%) (35%) Nurtec ODT/Vydura 248 178 40% 40% 228 167 36% 20 10 * * Abrysvo 131 145 (9%) (6%) 63 131 (52%) 68 14 * * All other Primary Care 672 765 (12%) (9%) 240 315 (24%) 432 450 (4%) 1% Specialty Care $ 2,616 $ 2,406 9% 11% $ 1,367 $ 1,258 9% $ 1,249 $ 1,148 9% 14% Vyndaqel family(e) 1,486 1,137 31% 33% 986 751 31% 499 386 29% 36% Enbrel (Outside the U.S. and Canada) 140 159 (12%) (6%) ― ― ― 140 159 (12%) (6%) Zavicefta (Outside the U.S. and Canada) 135 125 8% 14% ― ― ― 135 125 8% 14% Xeljanz 128 194 (34%) (31%) 20 74 (73%) 108 120 (10%) (6%) Cibinqo 58 42 39% 42% 24 23 2% 34 19 85% 91% All other Specialty Care 669 749 (11%) (8%) 336 409 (18%) 332 340 (2%) 3% Oncology $ 3,494 $ 3,285 6% 8% $ 2,629 $ 2,412 9% $ 866 $ 873 (1%) 4% Ibrance 977 1,054 (7%) (6%) 659 679 (3%) 318 375 (15%) (10%) Xtandi(f) 458 418 9% 9% 458 418 9% ― ― ― ― Padcev 426 341 25% 25% 419 334 25% 7 7 ― 2% Lorbrena 222 164 36% 39% 92 59 55% 130 104 25% 29% Inlyta 219 237 (7%) (6%) 129 141 (8%) 90 96 (6%) (2%) Adcetris(g) 218 257 (15%) (15%) 213 252 (16%) 5 5 (9%) (3%) Bosulif 151 145 4% 5% 120 101 18% 31 44 (29%) (25%) Braftovi/Mektovi 136 116 17% 17% 128 111 15% 8 5 53% 65% Aromasin 108 82 31% 34% ― 1 (22%) 107 82 31% 34% Tukysa 102 106 (3%) (3%) 83 89 (7%) 20 17 16% 21% Elrexfio 60 13 * * 31 11 * 29 2 * * Talzenna 40 23 74% 77% 29 17 69% 11 6 89% 99% Tivdak 33 28 21% 22% 31 27 12% 3 ― * * All other Oncology 345 301 15% 17% 238 171 39% 107 130 (17%) (13%) Hospital and Biosimilars(a) $ 1,639 $ 1,706 (4%) (1%) $ 713 $ 661 8% $ 926 $ 1,045 (11%) (7%) Oncology biosimilars(i) 264 264 ― 2% 177 160 11% 87 104 (17%) (11%) Sulperazon (Outside the U.S. and Canada) 164 167 (2%) ― ― ― ― 164 167 (2%) ― Inflectra 153 158 (3%) (2%) 103 96 7% 50 62 (19%) (15%) Zithromax 158 200 (21%) (18%) ― ― (37%) 158 199 (21%) (18%) All other Hospital and Biosimilars 901 917 (2%) 1% 433 405 7% 468 512 (9%) (3%) Pfizer CentreOne(j) $ 257 $ 258 ― 2% $ 72 $ 71 2% $ 185 $ 187 (1%) 2% Pfizer Ignite $ 17 $ 17 (3%) (3%) $ 17 $ 17 (3%) $ ― $ ― ― ― Biopharma $ 13,441 $ 14,604 (8%) (6%) $ 8,285 $ 9,426 (12%) $ 5,156 $ 5,178 ― 4% PFIZER U.S. COMMERCIAL DIVISION 7,572 8,764 (14%) (14%) 7,572 8,764 (14%) ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 4,849 4,818 1% 5% ― ― ― 4,849 4,818 1% 5% GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 1,020 1,021 ― 2% 713 661 8% 307 360 (15%) (9%) Total Alliance revenues included above $ 2,113 $ 2,172 (3%) (2%) $ 1,727 $ 1,780 (3%) $ 386 $ 392 (1%) 3% Total Royalty revenues included above $ 308 $ 263 17% 17% $ 305 $ 263 16% $ 3 $ ― * *
Slide 3 — PFIZER INC. REVENUES
PFIZER INC. REVENUES SECOND QUARTER 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 14,653 $ 13,283 10% 10% $ 8,894 $ 7,892 13% $ 5,759 $ 5,391 7% 6% GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 14,305 $ 12,991 10% 10% $ 8,793 $ 7,828 12% $ 5,512 $ 5,163 7% 6% Primary Care $ 5,535 $ 4,947 12% 12% $ 3,430 $ 2,938 17% $ 2,105 $ 2,009 5% 4% Eliquis(b) 2,003 1,877 7% 6% 1,322 1,262 5% 681 615 11% 8% Prevnar family(c) 1,383 1,359 2% 2% 860 832 3% 523 527 (1%) ― Paxlovid 427 251 70% 71% 328 68 * 99 184 (46%) (45%) Comirnaty 381 195 96% 95% 176 58 * 205 137 49% 49% Nurtec ODT/Vydura 359 356 1% 1% 333 339 (2%) 25 17 48% 47% Abrysvo 143 56 * * 101 41 * 42 15 * * FSME-IMMUN/TicoVac 109 100 9% 6% 1 1 16% 108 99 9% 6% All other Primary Care 731 754 (3%) (3%) 308 337 (9%) 423 416 2% 2% Specialty Care $ 3,089 $ 2,821 9% 9% $ 1,561 $ 1,506 4% $ 1,527 $ 1,315 16% 15% Vyndaqel family(e) 1,615 1,323 22% 21% 990 861 15% 626 462 35% 32% Xeljanz 322 303 6% 6% 206 181 14% 115 122 (5%) (6%) Zavicefta (Outside the U.S. and Canada) 163 150 9% 10% ― ― ― 163 150 9% 10% Enbrel (Outside the U.S. and Canada) 154 179 (14%) (14%) ― ― ― 154 179 (14%) (14%) Genotropin 106 119 (10%) (10%) 18 28 (37%) 89 91 (2%) (1%) Cresemba 111 71 56% 55% ― ― ― 111 71 56% 55% Cibinqo 69 47 47% 46% 24 15 59% 44 32 41% 40% All other Specialty Care 549 629 (13%) (12%) 323 421 (23%) 225 208 8% 10% Oncology $ 4,034 $ 3,677 10% 10% $ 3,021 $ 2,741 10% $ 1,014 $ 936 8% 8% Ibrance 1,049 1,130 (7%) (8%) 696 741 (6%) 353 390 (9%) (11%) Xtandi(f) 566 495 14% 14% 566 495 14% ― ― ― ― Padcev 542 394 38% 38% 534 387 38% 7 7 9% 11% Lorbrena 251 169 49% 48% 100 70 43% 151 99 53% 52% Adcetris(g) 255 279 (9%) (9%) 248 271 (9%) 6 7 (11%) (9%) Inlyta 243 252 (4%) (4%) 132 151 (13%) 111 101 9% 10% Braftovi/Mektovi 182 148 23% 23% 171 142 21% 10 6 60% 67% Bosulif 149 167 (11%) (12%) 116 118 (1%) 32 49 (34%) (36%) Tukysa 132 121 9% 8% 107 97 11% 24 24 ― (2%) Aromasin 111 87 27% 28% 1 1 (10%) 111 87 27% 28% Elrexfio 85 22 * * 35 18 96% 50 5 * * Talzenna 46 32 44% 43% 34 25 37% 12 7 67% 62% Tivdak 46 33 39% 38% 43 32 34% 2 1 * * All other Oncology 380 347 10% 10% 237 194 22% 143 153 (7%) (6%) Hospital and Biosimilars(a) $ 1,647 $ 1,546 7% 7% $ 781 $ 643 21% $ 866 $ 902 (4%) (3%) Oncology biosimilars(i) 353 279 26% 27% 257 177 45% 97 103 (6%) (5%) Sulperazon (Outside the U.S. and Canada) 166 144 15% 16% ― ― ― 166 144 15% 16% Inflectra 139 97 43% 43% 100 43 * 39 54 (28%) (26%) Zithromax 56 74 (25%) (25%) ― ― * 56 74 (25%) (25%) All other Hospital and Biosimilars 934 951 (2%) (1%) 425 423 * 509 528 (4%) (3%) Pfizer CentreOne(j) $ 328 $ 278 18% 18% $ 81 $ 49 65% $ 247 $ 229 8% 8% Pfizer Ignite $ 20 $ 15 38% 38% $ 20 $ 15 38% $ ― $ ― ― ― Biopharma $ 14,305 $ 12,991 10% 10% $ 8,793 $ 7,828 12% $ 5,512 $ 5,163 7% 6% PFIZER U.S. COMMERCIAL DIVISION 8,011 7,185 12% 12% 8,011 7,185 12% ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 5,178 4,804 8% 7% ― ― ― 5,178 4,804 8% 7% GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 1,116 1,002 11% 11% 781 643 21% 334 359 (7%) (7%) Total Alliance revenues included above $ 2,273 $ 2,067 10% 9% $ 1,837 $ 1,680 9% $ 437 $ 387 13% 10% Total Royalty revenues included above $ 426 $ 345 23% 23% $ 423 $ 344 23% $ 3 $ 2 58% 53%
Slide 4 — PFIZER INC. REVENUES
PFIZER INC. REVENUES SIX MONTHS 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 28,367 $ 28,162 1% 2% $ 17,268 $ 17,406 (1%) $ 11,100 $ 10,756 3% 5% GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 27,746 $ 27,595 1% 1% $ 17,078 $ 17,254 (1%) $ 10,668 $ 10,341 3% 5% Primary Care $ 11,226 $ 12,154 (8%) (7%) $ 7,006 $ 8,032 (13%) $ 4,220 $ 4,121 2% 4% Eliquis(b) 3,926 3,917 ― 1% 2,621 2,675 (2%) 1,305 1,242 5% 7% Prevnar family(c) 3,043 3,050 ― ― 2,030 1,981 2% 1,013 1,069 (5%) (3%) Comirnaty 945 548 72% 74% 406 176 * 540 373 45% 47% Paxlovid(d) 918 2,286 (60%) (59%) 675 1,868 (64%) 244 418 (42%) (39%) Nurtec ODT/Vydura 607 533 14% 14% 561 506 11% 46 27 68% 69% Abrysvo 274 201 36% 39% 164 172 (5%) 110 29 * * FSME-IMMUN/TicoVac 172 165 4% 4% 2 2 1% 170 163 4% 4% All other Primary Care 1,340 1,453 (8%) (6%) 547 652 (16%) 793 801 (1%) 2% Specialty Care $ 5,705 $ 5,227 9% 10% $ 2,928 $ 2,764 6% $ 2,777 $ 2,463 13% 15% Vyndaqel family(e) 3,101 2,460 26% 27% 1,976 1,612 23% 1,125 848 33% 34% Xeljanz 450 497 (10%) (9%) 226 255 (11%) 223 242 (8%) (6%) Zavicefta (Outside the U.S. and Canada) 299 275 8% 12% ― ― ― 299 275 8% 12% Enbrel (Outside the U.S. and Canada) 294 338 (13%) (10%) ― ― ― 294 338 (13%) (10%) Genotropin 201 239 (16%) (13%) 29 58 (51%) 172 181 (5%) (1%) Cresemba 184 146 26% 27% ― ― ― 184 146 26% 27% Cibinqo 127 89 43% 44% 48 38 25% 79 50 57% 59% All other Specialty Care 1,050 1,183 (11%) (10%) 649 800 (19%) 401 384 5% 8% Oncology $ 7,528 $ 6,962 8% 9% $ 5,649 $ 5,154 10% $ 1,879 $ 1,808 4% 6% Ibrance 2,026 2,184 (7%) (7%) 1,354 1,420 (5%) 671 765 (12%) (11%) Xtandi(f) 1,023 913 12% 12% 1,023 913 12% ― ― ― ― Padcev 967 735 32% 32% 953 721 32% 14 14 5% 6% Lorbrena 473 332 42% 44% 192 129 49% 281 203 38% 40% Adcetris(g) 472 536 (12%) (12%) 461 524 (12%) 11 12 (10%) (7%) Inlyta 462 489 (6%) (5%) 261 292 (11%) 201 197 2% 4% Braftovi/Mektovi 317 264 20% 21% 299 252 19% 18 12 57% 66% Bosulif 300 313 (4%) (4%) 236 219 8% 64 93 (32%) (31%) Tukysa 234 227 3% 3% 190 186 2% 44 41 6% 7% Aromasin 219 170 29% 31% 1 1 (16%) 218 169 29% 31% Elrexfio 145 35 * * 66 29 * 79 6 * * Talzenna 86 55 56% 57% 63 42 50% 23 13 77% 78% Tivdak 79 60 31% 31% 74 60 24% 5 1 * * All other Oncology 725 648 12% 13% 475 365 30% 250 283 (12%) (9%) Hospital and Biosimilars(a) $ 3,286 $ 3,252 1% 3% $ 1,494 $ 1,304 15% $ 1,792 $ 1,948 (8%) (5%) Oncology biosimilars(i) 617 543 14% 15% 434 336 29% 183 207 (12%) (8%) Sulperazon (Outside the U.S. and Canada) 330 311 6% 7% ― ― ― 330 311 6% 7% Inflectra 291 255 14% 15% 202 140 45% 89 116 (23%) (20%) Zithromax 213 274 (22%) (20%) ― ― (75%) 213 274 (22%) (20%) All other Hospital and Biosimilars 1,835 1,868 (2%) ― 858 828 4% 977 1,040 (6%) (3%) Pfizer CentreOne(j) $ 585 $ 535 9% 10% $ 153 $ 120 28% $ 432 $ 416 4% 5% Pfizer Ignite $ 37 $ 32 16% 16% $ 37 $ 32 16% $ ― $ ― ― ― Biopharma $ 27,746 $ 27,595 1% 1% $ 17,078 $ 17,254 (1%) $ 10,668 $ 10,341 3% 5% PFIZER U.S. COMMERCIAL DIVISION 15,583 15,950 (2%) (2%) 15,583 15,950 (2%) ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 10,027 9,622 4% 6% ― ― ― 10,027 9,622 4% 6% GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 2,136 2,023 6% 7% 1,494 1,304 15% 641 719 (11%) (8%) Total Alliance revenues included above $ 4,386 $ 4,240 3% 4% $ 3,563 $ 3,461 3% $ 823 $ 779 6% 7% Total Royalty revenues included above $ 734 $ 608 21% 21% $ 728 $ 606 20% $ 6 $ 2 * *
Slide 5 — PFIZER INC. REVENUES
PFIZER INC. REVENUES THIRD QUARTER 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 16,654 $ 17,702 (6%) (7%) $ 10,691 $ 12,064 (11%) $ 5,963 $ 5,638 6% 2% GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 16,310 $ 17,392 (6%) (7%) $ 10,599 $ 11,964 (11%) $ 5,711 $ 5,428 5% 2% Primary Care $ 7,642 $ 9,054 (16%) (16%) $ 5,343 $ 6,767 (21%) $ 2,299 $ 2,287 ― (3%) Eliquis(b) 2,015 1,617 25% 22% 1,292 1,002 29% 723 616 17% 11% Prevnar family(c) 1,742 1,803 (3%) (4%) 1,155 1,308 (12%) 587 495 18% 17% Paxlovid(d) 1,225 2,703 (55%) (55%) 1,122 2,313 (52%) 104 389 (73%) (73%) Comirnaty 1,151 1,422 (19%) (20%) 870 1,164 (25%) 282 258 9% 5% Nurtec ODT/Vydura 412 337 22% 22% 383 314 22% 29 23 26% 22% Abrysvo 279 356 (22%) (22%) 210 318 (34%) 68 38 81% 75% FSME-IMMUN/TicoVac 100 81 24% 15% 1 1 81% 99 80 23% 15% All other Primary Care 718 735 (2%) (4%) 310 348 (11%) 408 387 5% 2% Specialty Care $ 3,130 $ 3,003 4% 2% $ 1,623 $ 1,688 (4%) $ 1,507 $ 1,316 15% 10% Vyndaqel family(e) 1,591 1,447 10% 7% 948 960 (1%) 643 486 32% 25% Xeljanz 313 321 (3%) (4%) 205 203 1% 108 118 (9%) (13%) Zavicefta (Outside the U.S. and Canada) 158 152 5% 3% ― ― ― 158 152 5% 3% Enbrel (Outside the U.S. and Canada) 154 169 (9%) (12%) ― ― ― 154 169 (9%) (12%) Genotropin 128 119 7% 6% 31 27 14% 97 92 5% 3% Octagam 113 221 (49%) (49%) 113 221 (49%) ― ― ― ― Cresemba 83 67 23% 17% ― ― ― 83 67 23% 17% Cibinqo 79 63 26% 24% 30 23 34% 49 40 21% 18% All other Specialty Care 510 445 15% 14% 294 253 16% 216 192 13% 11% Oncology $ 3,938 $ 3,758 5% 4% $ 2,888 $ 2,850 1% $ 1,051 $ 909 16% 11% Ibrance 1,057 1,087 (3%) (5%) 670 717 (7%) 387 371 4% (1%) Xtandi(f) 578 561 3% 3% 578 561 3% ― ― ― ― Padcev 464 409 13% 13% 449 407 10% 16 2 * * Lorbrena 268 206 30% 28% 103 82 25% 165 124 34% 30% Inlyta 226 247 (8%) (9%) 124 150 (17%) 102 97 6% 3% Adcetris(g) 215 268 (20%) (20%) 210 260 (19%) 5 8 (37%) (37%) Braftovi/Mektovi 202 173 17% 17% 190 165 15% 12 8 52% 53% Bosulif 150 161 (7%) (8%) 117 113 3% 34 48 (30%) (33%) Tukysa 110 124 (11%) (12%) 79 97 (19%) 32 27 18% 11% Aromasin 114 87 31% 30% ― 1 (41%) 114 87 32% 30% Orgovyx(h) 112 57 97% 97% 112 57 97% ― ― ― ― Elrexfio 85 40 * * 37 26 40% 48 14 * * Talzenna 47 36 32% 30% 33 28 21% 14 8 70% 60% Tivdak 37 34 8% 8% 32 32 (1%) 5 2 * * All other Oncology 272 268 1% ― 156 155 1% 116 114 2% ― Hospital and Biosimilars(a) $ 1,600 $ 1,577 1% ― $ 745 $ 660 13% $ 854 $ 917 (7%) (9%) Oncology biosimilars(i) 315 285 11% 10% 214 176 22% 101 109 (7%) (10%) Sulperazon (Outside the U.S. and Canada) 154 156 (2%) (2%) ― ― ― 154 156 (2%) (2%) Inflectra 173 126 37% 37% 152 65 * 22 61 (65%) (66%) Zithromax 73 83 (13%) (14%) ― ― ― 73 83 (13%) (14%) All other Hospital and Biosimilars 885 926 (4%) (6%) 379 418 (9%) 506 507 ― (2%) Pfizer CentreOne(j) $ 344 $ 285 21% 18% $ 92 $ 76 21% $ 253 $ 210 21% 17% Pfizer Ignite $ ― $ 25 (99%) (99%) $ ― $ 25 (99%) $ ― $ ― ― ― Biopharma $ 16,310 $ 17,392 (6%) (7%) $ 10,599 $ 11,964 (11%) $ 5,711 $ 5,428 5% 2% PFIZER U.S. COMMERCIAL DIVISION 9,854 11,304 (13%) (13%) 9,854 11,304 (13%) ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 5,381 5,077 6% 2% ― ― ― 5,381 5,077 6% 2% GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 1,075 1,011 6% 5% 745 660 13% 330 351 (6%) (9%) Total Alliance revenues included above $ 2,298 $ 1,900 21% 19% $ 1,817 $ 1,474 23% $ 481 $ 427 13% 6% Total Royalty revenues included above $ 436 $ 384 13% 13% $ 434 $ 383 13% $ 2 $ 2 26% 24%
Slide 6 — PFIZER INC. REVENUES
PFIZER INC. REVENUES NINE MONTHS 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 45,022 $ 45,864 (2%) (2%) $ 27,959 $ 29,470 (5%) $ 17,063 $ 16,394 4% 4% GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 44,056 $ 44,987 (2%) (2%) $ 27,677 $ 29,218 (5%) $ 16,379 $ 15,769 4% 4% Primary Care $ 18,869 $ 21,208 (11%) (11%) $ 12,349 $ 14,799 (17%) $ 6,519 $ 6,408 2% 2% Eliquis(b) 5,941 5,534 7% 7% 3,913 3,677 6% 2,028 1,857 9% 8% Prevnar family(c) 4,786 4,853 (1%) (1%) 3,185 3,289 (3%) 1,601 1,564 2% 3% Paxlovid(d) 2,144 4,989 (57%) (57%) 1,796 4,181 (57%) 347 807 (57%) (56%) Comirnaty 2,097 1,970 6% 6% 1,275 1,339 (5%) 821 631 30% 30% Nurtec ODT/Vydura 1,019 870 17% 17% 945 820 15% 74 50 49% 48% Abrysvo 553 557 (1%) ― 374 490 (24%) 178 66 * * FSME-IMMUN/TicoVac 272 246 11% 8% 3 3 17% 269 244 10% 7% All other Primary Care 2,058 2,188 (6%) (5%) 858 999 (14%) 1,200 1,189 1% 2% Specialty Care $ 8,834 $ 8,230 7% 7% $ 4,551 $ 4,451 2% $ 4,284 $ 3,779 13% 13% Vyndaqel family(e) 4,692 3,907 20% 19% 2,924 2,572 14% 1,767 1,334 32% 31% Xeljanz 763 818 (7%) (7%) 431 459 (6%) 331 360 (8%) (8%) Zavicefta (Outside the U.S. and Canada) 457 427 7% 9% ― ― ― 457 427 7% 9% Enbrel (Outside the U.S. and Canada) 448 507 (12%) (11%) ― ― ― 448 507 (12%) (11%) Genotropin 329 358 (8%) (7%) 60 85 (30%) 269 272 (1%) ― Octagam 298 400 (26%) (26%) 298 400 (26%) ― ― ― ― Cresemba 267 213 25% 24% ― ― ― 267 213 25% 24% Cibinqo 206 152 36% 36% 79 61 28% 127 90 41% 41% All other Specialty Care 1,376 1,449 (5%) (4%) 759 874 (13%) 617 575 7% 9% Oncology $ 11,467 $ 10,720 7% 7% $ 8,537 $ 8,003 7% $ 2,930 $ 2,717 8% 8% Ibrance 3,083 3,272 (6%) (6%) 2,024 2,136 (5%) 1,058 1,135 (7%) (8%) Xtandi(f) 1,602 1,474 9% 9% 1,602 1,474 9% ― ― ― ― Padcev 1,432 1,144 25% 25% 1,402 1,128 24% 30 16 88% 89% Lorbrena 741 538 38% 38% 294 211 39% 447 327 37% 37% Inlyta 688 736 (7%) (6%) 385 442 (13%) 303 294 3% 4% Adcetris(g) 687 804 (15%) (14%) 671 784 (14%) 16 20 (21%) (18%) Braftovi/Mektovi 519 437 19% 19% 489 417 17% 30 20 55% 61% Bosulif 450 474 (5%) (5%) 353 333 6% 97 141 (31%) (32%) Tukysa 344 351 (2%) (2%) 269 283 (5%) 76 68 11% 9% Aromasin 333 257 30% 30% 1 2 (25%) 332 255 30% 31% Orgovyx(h) 285 136 * * 285 136 * ― ― ― ― Elrexfio 230 76 * * 102 55 85% 128 20 * * Talzenna 133 91 47% 46% 96 69 39% 37 21 74% 71% Tivdak 115 94 23% 22% 106 92 15% 10 2 * * All other Oncology 824 837 (2%) (1%) 458 440 4% 366 397 (8%) (7%) Hospital and Biosimilars(a) $ 4,886 $ 4,829 1% 2% $ 2,240 $ 1,964 14% $ 2,646 $ 2,865 (8%) (6%) Oncology biosimilars(i) 932 828 13% 13% 648 512 27% 284 316 (10%) (9%) Sulperazon (Outside the U.S. and Canada) 484 468 3% 4% ― ― ― 484 468 3% 4% Inflectra 465 382 22% 23% 354 205 73% 111 177 (38%) (36%) Zithromax 286 357 (20%) (19%) ― 1 (71%) 286 357 (20%) (19%) All other Hospital and Biosimilars 2,719 2,794 (3%) (2%) 1,237 1,247 (1%) 1,482 1,547 (4%) (3%) Pfizer CentreOne(j) $ 929 $ 820 13% 13% $ 245 $ 195 25% $ 684 $ 625 9% 9% Pfizer Ignite $ 37 $ 56 (34%) (34%) $ 37 $ 56 (34%) $ ― $ ― ― ― Biopharma $ 44,056 $ 44,987 (2%) (2%) $ 27,677 $ 29,218 (5%) $ 16,379 $ 15,769 4% 4% PFIZER U.S. COMMERCIAL DIVISION 25,437 27,254 (7%) (7%) 25,437 27,254 (7%) ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 15,408 14,699 5% 5% ― ― ― 15,408 14,699 5% 5% GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 3,211 3,034 6% 6% 2,240 1,964 14% 971 1,070 (9%) (8%) Total Alliance revenues included above $ 6,684 $ 6,140 9% 9% $ 5,381 $ 4,935 9% $ 1,304 $ 1,205 8% 6% Total Royalty revenues included above $ 1,170 $ 992 18% 18% $ 1,162 $ 989 18% $ 8 $ 4 * *
Slide 7 — PFIZER INC. REVENUES
PFIZER INC. REVENUES FOURTH QUARTER 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 17,557 $ 17,763 (1%) (3%) $ 9,119 $ 9,221 (1%) $ 8,438 $ 8,542 (1%) (4%) GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 17,144 $ 17,413 (2%) (3%) $ 9,031 $ 9,114 (1%) $ 8,113 $ 8,299 (2%) (5%) Primary Care $ 7,932 $ 8,904 (11%) (13%) $ 3,546 $ 3,982 (11%) $ 4,387 $ 4,922 (11%) (14%) Eliquis(b) 2,020 1,832 10% 8% 1,235 1,126 10% 785 705 11% 4% Prevnar family(c) 1,708 1,558 10% 8% 966 944 2% 742 614 21% 18% Comirnaty 2,271 3,383 (33%) (35%) 387 665 (42%) 1,883 2,718 (31%) (33%) Paxlovid 218 727 (70%) (70%) 95 435 (78%) 123 293 (58%) (59%) Nurtec ODT/Vydura 405 392 3% 3% 377 373 1% 27 20 40% 35% Abrysvo 481 198 * * 168 104 61% 313 94 * * FSME-IMMUN/TicoVac 47 34 38% 29% ― ― ― 47 34 39% 29% All other Primary Care 783 779 ― (1%) 316 335 (6%) 467 444 5% 2% Specialty Care $ 3,361 $ 3,040 11% 8% $ 1,606 $ 1,582 2% $ 1,755 $ 1,458 20% 16% Vyndaqel family(e) 1,688 1,545 9% 7% 910 975 (7%) 778 570 37% 30% Xeljanz 324 349 (7%) (8%) 194 221 (13%) 131 128 2% (1%) Zavicefta (Outside the U.S. and Canada) 181 159 14% 10% ― ― ― 181 159 14% 10% Enbrel (Outside the U.S. and Canada) 180 183 (2%) (5%) ― ― ― 180 183 (2%) (5%) Genotropin 117 112 5% 2% 19 10 81% 98 101 (3%) (6%) Octagam 120 109 10% 10% 120 109 10% ― ― ― ― Cresemba 83 67 23% 17% ― ― ― 83 67 23% 17% Cibinqo 78 64 23% 22% 37 29 28% 42 35 19% 17% All other Specialty Care 590 451 31% 30% 327 238 38% 263 213 23% 21% Oncology $ 4,066 $ 3,855 5% 5% $ 3,061 $ 2,936 4% $ 1,004 $ 919 9% 6% Ibrance 1,040 1,095 (5%) (7%) 686 713 (4%) 354 382 (7%) (12%) Xtandi(f) 592 565 5% 5% 592 565 5% ― ― ― ― Padcev 508 444 15% 15% 500 433 16% 8 11 (24%) (23%) Lorbrena 282 192 46% 45% 112 95 18% 169 97 74% 70% Inlyta 235 242 (3%) (4%) 131 145 (10%) 104 97 8% 6% Adcetris(g) 220 285 (23%) (23%) 213 276 (23%) 6 9 (33%) (31%) Braftovi/Mektovi 197 170 16% 16% 183 163 12% 14 7 99% 97% Bosulif 161 171 (6%) (6%) 135 128 6% 26 44 (39%) (40%) Tukysa 119 129 (8%) (9%) 84 106 (21%) 35 23 55% 47% Aromasin 117 90 30% 30% 1 1 (12%) 116 89 30% 30% Orgovyx(h) 136 64 * * 136 64 * ― ― ― ― Elrexfio 74 57 30% 30% 41 32 26% 33 25 34% 37% Talzenna 49 27 83% 80% 36 18 97% 13 9 51% 43% Tivdak 32 36 (13%) (12%) 34 34 ― (2) 2 * * All other Oncology 303 286 6% 5% 178 163 9% 126 123 2% ― Hospital and Biosimilars(a) $ 1,784 $ 1,614 11% 10% $ 817 $ 613 33% $ 967 $ 1,001 (3%) (5%) Oncology biosimilars(i) 369 209 77% 76% 266 116 * 104 93 11% 8% Sulperazon (Outside the U.S. and Canada) 169 170 ― ― ― ― ― 169 170 ― ― Inflectra 181 127 42% 42% 157 64 * 24 64 (63%) (63%) Zithromax 113 122 (7%) (8%) ― ― ― 113 122 (7%) (8%) All other Hospital and Biosimilars 952 986 (3%) (4%) 394 434 (9%) 557 552 1% (1%) Pfizer CentreOne(j) $ 409 $ 325 26% 22% $ 84 $ 82 2% $ 325 $ 243 34% 29% Pfizer Ignite $ 4 $ 26 (83%) (83%) $ 4 $ 26 (83%) $ ― $ ― ― ― Biopharma $ 17,144 $ 17,413 (2%) (3%) $ 9,031 $ 9,114 (1%) $ 8,113 $ 8,299 (2%) (5%) PFIZER U.S. COMMERCIAL DIVISION 8,214 8,501 (3%) (3%) 8,214 8,501 (3%) ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 7,749 7,926 (2%) (5%) ― ― ― 7,749 7,926 (2%) (5%) GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 1,181 986 20% 19% 817 613 33% 364 373 (2%) (5%) Total Alliance revenues included above $ 2,582 $ 2,248 15% 14% $ 1,828 $ 1,641 11% $ 753 $ 607 24% 19% Total Royalty revenues included above $ 480 $ 431 11% 11% $ 477 $ 429 11% $ 3 $ 2 52% 48%
Slide 8 — PFIZER INC. REVENUES
PFIZER INC. REVENUES TWELVE MONTHS 2025 and 2024 UNAUDITED (millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL % Change % Change % Change 2025 2024 Total Oper. 2025 2024 Total 2025 2024 Total Oper. TOTAL REVENUES $ 62,579 $ 63,627 (2%) (2%) $ 37,078 $ 38,691 (4%) $ 25,501 $ 24,936 2% 1% GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a) $ 61,199 $ 62,400 (2%) (2%) $ 36,708 $ 38,332 (4%) $ 24,491 $ 24,068 2% 1% Primary Care $ 26,801 $ 30,112 (11%) (12%) $ 15,895 $ 18,781 (15%) $ 10,906 $ 11,330 (4%) (5%) Eliquis(b) 7,961 7,366 8% 7% 5,148 4,803 7% 2,813 2,563 10% 7% Prevnar family(c) 6,494 6,411 1% 1% 4,151 4,233 (2%) 2,342 2,178 8% 7% Comirnaty 4,367 5,353 (18%) (20%) 1,663 2,004 (17%) 2,705 3,349 (19%) (21%) Paxlovid(d) 2,362 5,716 (59%) (59%) 1,891 4,616 (59%) 470 1,100 (57%) (57%) Nurtec ODT/Vydura 1,424 1,263 13% 13% 1,322 1,193 11% 102 69 46% 44% Abrysvo 1,033 755 37% 36% 542 594 (9%) 491 160 * * FSME-IMMUN/TicoVac 319 280 14% 10% 3 3 13% 316 277 14% 10% All other Primary Care 2,841 2,968 (4%) (4%) 1,174 1,335 (12%) 1,667 1,633 2% 2% Specialty Care $ 12,196 $ 11,270 8% 8% $ 6,157 $ 6,034 2% $ 6,038 $ 5,236 15% 14% Vyndaqel family(e) 6,380 5,451 17% 16% 3,834 3,547 8% 2,546 1,904 34% 30% Xeljanz 1,087 1,168 (7%) (7%) 625 680 (8%) 462 488 (5%) (6%) Zavicefta (Outside the U.S. and Canada) 638 586 9% 9% ― ― ― 638 586 9% 9% Enbrel (Outside the U.S. and Canada) 627 690 (9%) (9%) ― ― ― 627 690 (9%) (9%) Genotropin 446 470 (5%) (5%) 79 96 (18%) 367 374 (2%) (1%) Octagam 418 509 (18%) (18%) 418 509 (18%) ― ― ― ― Cresemba 349 281 24% 22% ― ― ― 349 281 24% 22% Cibinqo 284 215 32% 32% 115 90 28% 169 126 35% 34% All other Specialty Care 1,966 1,900 3% 4% 1,087 1,112 (2%) 880 788 12% 12% Oncology $ 15,532 $ 14,575 7% 6% $ 11,598 $ 10,939 6% $ 3,934 $ 3,636 8% 7% Ibrance 4,122 4,367 (6%) (6%) 2,710 2,849 (5%) 1,412 1,518 (7%) (9%) Xtandi(f) 2,194 2,039 8% 8% 2,194 2,039 8% ― ― ― ― Padcev 1,940 1,588 22% 22% 1,902 1,561 22% 38 27 42% 43% Lorbrena 1,023 731 40% 40% 407 306 33% 616 424 45% 44% Inlyta 923 978 (6%) (6%) 516 588 (12%) 407 391 4% 4% Adcetris(g) 907 1,089 (17%) (17%) 885 1,059 (16%) 23 30 (25%) (23%) Braftovi/Mektovi 716 607 18% 18% 672 580 16% 45 27 67% 71% Bosulif 611 645 (5%) (5%) 488 460 6% 124 185 (33%) (34%) Tukysa 463 480 (4%) (4%) 352 389 (10%) 111 91 22% 18% Aromasin 450 347 30% 30% 2 2 (21%) 448 345 30% 30% Orgovyx(h) 421 201 * * 421 201 * ― ― ― ― Elrexfio 304 133 * * 143 88 63% 161 45 * * Talzenna 182 117 55% 54% 133 88 51% 50 30 67% 63% Tivdak 147 131 13% 13% 140 126 11% 7 5 59% 59% All other Oncology 1,127 1,122 ― 1% 635 603 5% 492 519 (5%) (5%) Hospital and Biosimilars(a) $ 6,671 $ 6,443 4% 4% $ 3,057 $ 2,577 19% $ 3,613 $ 3,865 (7%) (6%) Oncology biosimilars(i) 1,301 1,037 25% 26% 914 628 46% 387 409 (5%) (5%) Sulperazon (Outside the U.S. and Canada) 653 637 2% 3% ― ― ― 653 637 2% 3% Inflectra 646 509 27% 27% 511 268 91% 134 241 (44%) (43%) Zithromax 399 480 (17%) (16%) ― 1 (66%) 399 479 (17%) (16%) All other Hospital and Biosimilars 3,671 3,780 (3%) (2%) 1,631 1,681 (3%) 2,039 2,099 (3%) (2%) Pfizer CentreOne(j) $ 1,338 $ 1,146 17% 15% $ 329 $ 278 18% $ 1,010 $ 868 16% 15% Pfizer Ignite $ 41 $ 82 (50%) (50%) $ 41 $ 82 (50%) $ ― $ ― ― ― Biopharma $ 61,199 $ 62,400 (2%) (2%) $ 36,708 $ 38,332 (4%) $ 24,491 $ 24,068 2% 1% PFIZER U.S. COMMERCIAL DIVISION 33,651 35,754 (6%) (6%) 33,651 35,754 (6%) ― ― ― ― PFIZER INTERNATIONAL COMMERCIAL DIVISION 23,157 22,625 2% 1% ― ― ― 23,157 22,625 2% 1% GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(k) 4,392 4,020 9% 9% 3,057 2,577 19% 1,335 1,443 (8%) (7%) Total Alliance revenues included above $ 9,266 $ 8,388 10% 10% $ 7,209 $ 6,575 10% $ 2,057 $ 1,813 13% 11% Total Royalty revenues included above $ 1,650 $ 1,423 16% 16% $ 1,639 $ 1,418 16% $ 11 $ 6 94% 91%
Slide 9 — PFIZER INC.
(a) In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. Effective January 1, 2026, the commercial structure within the Biopharma reportable segment is composed of the Pfizer U.S. Commercial Division, the Pfizer International Commercial Division and the Global Hospital and Biosimilars Division. The amounts presented in the 2025 Product Revenues Tables have been recasted to conform to Pfizer’s new commercial operating structure. For additional information regarding our commercial organizational structure, see the Item 1. Business––Commercial Operations section of our 2025 Annual Report on Form 10-K (available at www.pfizer.com). (b) Reflects alliance revenues and product revenues. (c) Prevnar family includes revenues from Prevnar 20/Prevenar 20 (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult). (d) 2024 included a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million emergency use authorization-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023. 2024 also included $442 million of revenue recorded in the third quarter of 2024 in connection with the creation of a U.S. Strategic National Stockpile of 1.0 million treatment courses, which we supplied at no cost to the U.S. government or taxpayers. (e) Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan. (f) Primarily reflects alliance revenues and royalty revenues. (g) Reflects product revenues and royalty revenues. (h) Reflects alliance revenues. (i) Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym. (j) Pfizer CentreOne (PC1) includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. (k) Includes the commercial organization covering Pfizer’s Hospital and Biosimilars product portfolio of off-patent branded and generic sterile injectables and biosimilars except in China, Hong Kong, and certain other international markets, which are part of the Pfizer International Commercial Division. * Indicates calculation not meaningful or results are greater than 100%. Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts. PFIZER INC. NOTES TO REVENUES TABLE INFORMATION (UNAUDITED)